
News|Articles|August 15, 2013
INFOGRAPHIC: Oral oncolytics
The pros and cons of oral oncolytics and intravenous drugs.
Advertisement
The pros and cons of oral oncolytics and intravenous drugs.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
2
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
3
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
4
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
5



























